Carruthers Dermatology Centre, Inc., Vancouver, BC, Canada.
Dermatol Surg. 2010 Jul;36(7):1130-7. doi: 10.1111/j.1524-4725.2010.01597.x.
Literature cautions against applying lidocaine 15%/prilocaine 5% over an area larger than 300 cm(2). The area of the face, neck, and chest is 400 cm(2) or greater.
To investigate the safety of lidocaine 15%/prilocaine 5% topical anesthetic ointment used as anesthesia for intense pulsed light (IPL) treatment.
Lidocaine 15%/prilocaine 5% ointment was applied to the face only (n=10) for 30 +/- 15 minutes or to the face, neck, and chest (n=10) for a total of 60 +/- 15 minutes before IPL. Blood lidocaine and prilocaine levels were measured. Adverse events were recorded.
For the entire cohort, blood was drawn 25.6 +/- 6.6 minutes after IPL was completed. In the face only group, the mean lidocaine level was 0.122 +/- 0.125 microg/mL, and the mean prilocaine level was 0.048 +/- 0.029 microg/mL. In the face, neck, and chest group, the mean lidocaine level was 0.272 +/- 0.208 microg/mL, and the mean prilocaine level was 0.087 +/- 0.060 microg/mL. No adverse events related to systemic toxicity were observed or reported to the nurse. At the 24-hour follow-up, no subject reported symptoms of systemic toxicity after leaving the clinic.
Under the conditions of this study, topical lidocaine 15%/prilocaine 5% produces low levels of systemic absorption.
文献警告不要将利多卡因 15%/丙胺卡因 5%涂在超过 300cm²的区域。面部、颈部和胸部的面积大于 400cm²。
研究利多卡因 15%/丙胺卡因 5%局部麻醉软膏用于强脉冲光 (IPL) 治疗的安全性。
利多卡因 15%/丙胺卡因 5%软膏仅涂于面部（n=10），持续 30+/-15 分钟，或涂于面部、颈部和胸部（n=10），总时间为 60+/-15 分钟，然后进行 IPL。测量血中利多卡因和丙胺卡因的浓度。记录不良反应。
对于整个队列，在 IPL 完成后 25.6+/-6.6 分钟抽取血液。在仅面部组中，平均利多卡因浓度为 0.122+/-0.125μg/mL，平均丙胺卡因浓度为 0.048+/-0.029μg/mL。在面部、颈部和胸部组中，平均利多卡因浓度为 0.272+/-0.208μg/mL，平均丙胺卡因浓度为 0.087+/-0.060μg/mL。未观察到或向护士报告与全身毒性相关的不良反应。在 24 小时随访时，没有患者报告离开诊所后出现全身毒性症状。
在本研究条件下，局部应用利多卡因 15%/丙胺卡因 5%会产生低水平的全身吸收。
